Abstract PD5-09: Molecular features of response to palbociclib + fulvestrant ± inavolisib in hormone receptor-positive, HER2-negative, PIK3CA -mutated advanced breast cancer as assessed from baseline circulating tumor DNA in the pivotal Phase 3 INAVO120 trial
Year: 2026
Type: conference-abstract
Source: Clinical Cancer Research
Institutions: Genentech, Institute of Cancer Research, Royal Marsden Hospital, Emory University, Winship Cancer Institute, Goethe University Frankfurt, German Breast Group, Memorial Sloan Kettering Cancer Center, Seoul National University, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Queen Mary University of London, Barts Cancer Institute, The University of Melbourne, Peter MacCallum Cancer Centre, Harvard University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7129513652